Diagnosis, Treatment and Clinical Features of Cutaneous Leishmaniasis in Saudi Arabia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cutaneous leishmaniasis (CL) has been one of the most common parasitic diseases in Saudi Arabia. This study exhibits the clinical features, diagnosis, cytokine profile and treatment of CL patients in Al-Taif province. Ninety CL suspects at a tertiary care general hospital were enrolled in one-year study. Patients were interviewed, clinically-examined, and subjected to laboratory tests: skin scraping smear microscopy, OligoC-TesT commercial PCR (Coris BioConcept) and kinetoplast DNA (kDNA) PCR for Leishmania diagnosis. Interferon-gamma (RayBio; Human IFN-γ) and nitric oxide (NO) levels in patients’ sera were evaluated before treatment with sodium stibogluconate (pentostam) with 20-day intramuscular drug regimen. Positive rates of microscopy, commercial PCR and kDNA PCR were 74.4%, 95.5% and 100%, respectively. Patients came to hospital mostly in winter (45.0%). CL was frequently exhibited in Saudi patients (78.8%), male gender (70.7%), age <20 years (50.0%), rural-dwellers (75.5%) and patients with travel history (86.6%). Lesion was mostly single ulcer (93.3%), occurred in the face (67.7%). Upon pentostam treatment, 85.1% of ulcers showed rapid healing signs. Levels of IFN-γ and NO were significantly higher in the healing than the non-healing cases (P<0.001). The kDNA PCR proved more sensitive than microscopy and OligoC-TesT commercial PCR. Our results open perspectives for IFN-γ use as a biomarker predicting treatment response.
Abstract
Cutaneous leishmaniasis (CL) has been one of the most common parasitic diseases in Saudi Arabia. This study exhibits the clinical features, diagnosis, cytokine profile and treatment of CL patients in Al-Taif province. Ninety CL suspects at a tertiary care general hospital were enrolled in one-year study. Patients were interviewed, clinically-examined, and subjected to laboratory tests: skin scraping smear microscopy, OligoC-TesT commercial PCR (Coris BioConcept) and kinetoplast DNA (kDNA) PCR for Leishmania diagnosis. Interferon-gamma (RayBio; Human IFN-γ) and nitric oxide (NO) levels in patients’ sera were evaluated before treatment with sodium stibogluconate (pentostam) with 20-day intramuscular drug regimen. Positive rates of microscopy, commercial PCR and kDNA PCR were 74.4%, 95.5% and 100%, respectively. Patients came to hospital mostly in winter (45.0%). CL was frequently exhibited in Saudi patients (78.8%), male gender (70.7%), age <20 years (50.0%), rural-dwellers (75.5%) and patients with travel history (86.6%). Lesion was mostly single ulcer (93.3%), occurred in the face (67.7%). Upon pentostam treatment, 85.1% of ulcers showed rapid healing signs. Levels of IFN-γ and NO were significantly higher in the healing than the non-healing cases (P<0.001). The kDNA PCR proved more sensitive than microscopy and OligoC-TesT commercial PCR. Our results open perspectives for IFN-γ use as a biomarker predicting treatment response.
참고문헌 (31)
- Reithinger R, "Cutaneous leishmaniasis", Lancet Infect Dis, 7, pp.581~596 (2007)[DOI]
- Alvar J, "Leishmaniasis worldwide and global estimates of its incidence", PLoS One, 7, pp.e35671~ (2012)[DOI]
- Dowlati Y, "Cutaneous leishmaniasis: clinical aspect", Clin Dermatol, 14, pp.425~431 (1996)[DOI]
- von Stebut E, "Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity", Eur J Dermatol, 17, pp.115~122 (2007)
- Carneiro PP, "The role of nitric oxide and reactive oxygen species in the killing of Leishmania braziliensis by monocytes from patients with cutaneous leishmaniasis", PLoS One, 11, pp.e0148084~ (2016)[DOI]
- Vega-Lopez F, "Diagnosis of cutaneous leishmaniasis", Curr Opin Infect Dis, 16, pp.97~101 (2003)[DOI]
- Reithinger R, "Molecular diagnosis of leishmaniasis: current status and future applications", J Clin Microbiol, 45, pp.21~25 (2007)[DOI]
- Copeland NK, "Leishmaniasis: treatment updates and clinical practice guidelines review", Curr Opin Infect Dis, 28, pp.426~437 (2015)[DOI]
- Ponte-Sucre A, "Drug resistance and treatment failure in leishmaniasis: A 21st century challenge", PLoS Negl Trop Dis, 11, pp.e0006052~ (2017)[DOI]
- Saab M, "Diagnosis of cutaneous leishmaniasis: why punch when you can scrape?", Am J Trop Med Hyg, 92, pp.518~522 (2015)[DOI]
- Aransay AM, "Detection and identification of Leishmania DNA within naturally infected sand flies by seminested PCR on minicircle kinetoplastic DNA", Appl Environ Microbiol, 66, pp.1933~1938 (2000)[DOI]
- Abuzaid AA, "Cutaneous leishmaniasis in Saudi Arabia: a comprehensive overview", Vector Borne Zoonotic Dis, 17, pp.673~684 (2017)[DOI]
- Amin TT, "Cutaneous leishmaniasis in Al Hassa, Saudi Arabia: epidemiological trends from 2000 to 2010", Asian Pac J Trop Med, 6, pp.667~672 (2013)[DOI]
- Haouas N, "Profile and geographical distribution of reported cutaneous leishmaniasis cases in northwestern Saudi Arabia, from 2010 to 2013", Asian Pac J Trop Med, 8, pp.287~291 (2015)[DOI]
- Bousslimi N, "Epidemiologic and clinical features of cutaneous leishmaniasis in southeastern Tunisia", Am J Trop Med Hyg, 83, pp.1034~1039 (2010)[DOI]
- Chaves LF, "Climate cycles and forecasts of cutaneous leishmaniasis, a nonstationary vector-borne disease", PLoS Med, 3, pp.e295~ (2006)[DOI]
- Zakai HA, "Cutaneous leishmaniasis in Saudi Arabia: current status", J Adv Lab Res Biol, 5, pp.29~34 (2014)
- Al-Gindan Y, "Cutaneous leishmaniasis in Al-Hassa, Saudi Arabia", Int J Dermatol, 23, pp.194~197 (1984)[DOI]
- Al-Gindan Y, "A case of mucocutaneous leishmaniasis in Saudi Arabia caused by Leishmania major and its response to treatment", Clin Exp Dermatol, 8, pp.185~188 (1983)[DOI]
- Morsy TA, "Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia", J Egypt Soc Parasitol, 25, pp.73~79 (1995)
- Khan W, "Epidemiology, pathology and treatment of cutaneous leishmaniasis in Taif region of Saudi Arabia", Iran J Parasitol, 9, pp.365~373 (2014)
- Fendri AH, "Leishmaniasis in Constantine (Algeria): review of five years (2006-2010) at the University Hospital", Bull Soc Pathol Exot, 105, pp.46~48 (2012)[DOI]
- Farahmand M, "An overview of a diagnostic and epidemiologic reappraisal of cutaneous leishmaniasis in Iran", Braz J Infect Dis, 15, pp.17~21 (2011)[DOI]
- Al-Tawfiq JA, "Cutaneous leishmaniasis: a 46-year study of the epidemiology and clinical features in Saudi Arabia (1956-2002)", Int J Infect Dis, 8, pp.244~250 (2004)[DOI]
- Rasti S, "Comparison of molecular, microscopic, and culture methods for diagnosis of cutaneous leishmaniasis", J Clin Lab Anal, 30, pp.610~615 (2016)[DOI]
- Bensoussan E, "Comparison of PCR assays for diagnosis of cutaneous leishmaniasis", J Clin Microbiol, 44, pp.1435~1439 (2006)[DOI]
- Franke ED, "Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis", Ann Intern Med, 113, pp.934~940 (1990)[DOI]
- Wortmann G, "A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel", Clin Infect Dis, 35, pp.261~267 (2002)[DOI]
- Decuypere S, "Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background", PLoS Negl Trop Dis, 6, pp.e1514~ (2012)[DOI]
- Kwieder M, "Analysis of cellular immune response in cutaneous leishmaniasis Syrian patients", Int J PharmTech Res, 8, pp.60~65 (2016)
- Taheri AR, "Plasma levels of interlukin-4 and interferon-<TEX>${\gamma}$<", TEX> in patients with chronic or healed cutaneous leishmaniasis, 2014, pp.17, 216~219